Welcome!

News Feed Item

Delcath Reports 2014 Second Quarter Results

- Conference Call and Webcast Today at 4:30 p.m. ET -

NEW YORK, Aug. 6, 2014 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal second quarter ended June 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:

  • Adoption of CHEMOSAT in Europe continued with 50 treatments performed in the first seven months of 2014, as compared to 22 treatments in the same period of 2013
  • Since initiation of European commercialization, 123 treatments performed on 83 patients as of July 31, 2014
  • Delcath-sponsored Phase 2 study in primary liver cancer (hepatocellular carcinoma or HCC) opened for enrollment at first center in Germany; Johan Wolfgang Goethe University Hospital in Frankfurt
  • Two investigator-initiated clinical trials initiated; Leiden University Medical Center, Leiden, Netherlands enrolls and treats first patient in study of CHEMOSAT to treat liver metastasis in colorectal cancer; Johan Wolfgang Goethe University Hospital in Frankfurt trial open for patient enrollment to study use of CHEMOSAT to treat HCC
  • Second quarter 2014 quarterly net cash utilization of $4.0 million; Company lowers average cash utilization guidance for the remainder of 2014 to $4 to $5 million a quarter; Cash as of June 30, 2014 was $27.3 million

"We continue to see steady clinical adoption of CHEMOSAT in Europe," commented Jennifer K. Simpson, Interim Co-President & Co-CEO.  "As of July 31st of this year, a total of 50 treatments, of which 22 were retreatments, were performed at leading European cancer centers.  This compares with 22 treatments and six retreatments during the first seven months of 2013.  We believe the growth in performed treatments reflects expanded European clinical experience with CHEMOSAT.  Our company-sponsored clinical program for HCC is also moving forward as the first site in Germany is now active and identifying appropriate patients for enrollment.  In addition to this first site, Johan Wolfgang Goethe University Hospital in Frankfurt, we expect to add additional German sites, as well as sites in the UK and US during the remainder of 2014.  Our goal is to have interim data from the company sponsored Phase 2 studies in the first half of 2015.  We are pleased that two leading centers in Europe have opened their investigator initiated trials and believe that data from these trials will support our European efforts and contribute to our clinical program." 

Financial Results

For the second quarter ended June 30, 2014, total product revenue was $251,000. The company did not record revenue in the year-ago second quarter. Operating expenses decreased by approximately 41% to $6.1 million from $10.3 million for the same period in 2013. The decrease is primarily due to a significant reduction in expenses related to the Company's NDA submission to the FDA, as well as the Company's overall cost management efforts. Operating loss was $5.9 million during the second quarter, as compared with an operating loss of $10.6 million in the same period of the prior year.

For the six months ended June 30, 2014, total product revenue was $561,000, as compared with $81,000 in the year-ago same period.  Operating expenses decreased by approximately 45% to $11.4 million from $20.8 million for the first half of 2013.  The operating loss for the first six months of 2014 was $11.0 million as compared with $20.8 million for the first half of 2013.

Cash and cash equivalents as of June 30, 2014 were $27.3 million. During the quarter, net cash used in operating activities was $4.0 million, a 62% reduction compared to $10.5 million in the comparable period in 2013. The decrease in cash utilization was in part due to a reduction in NDA submission-related costs, and improved organizational and operational efficiencies.

"Our cash utilization, which again was lower than our guidance, demonstrates our continuing efforts to reduce our operational costs and focus on key priorities. Recent expense reduction initiatives include a sublease agreement for 50% of our corporate offices for the remaining lease term of approximately seven years.  As a result of this transaction, we expect to achieve total net savings of $2.6 million over the lease term.  In addition, as a result of our successful efforts, we are revising our forecasted average quarterly cash utilization lower to a range of $4 to $5 million for the remaining quarters of 2014, as compared to our previous average quarterly cash utilization guidance of $5 to $6 million," said Graham G. Miao, Interim Co-President and Co-CEO.

Conference Call and Webcast

The Company will host a conference call today, August 6, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2014, and provide an update on recent corporate progress. 

The dial-in numbers for the conference call are 877-703-6105 (U.S. participants) and 857-244-7304 (international participants); both numbers require passcode: 33935953. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at http://www.delcath.com/investors/events/.

A taped replay of the call will be available beginning approximately two hours after the call's conclusion and will be available for seven days. Dial-in numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode for both U.S. and International callers is 93152789.  An archived webcast will also be available at http://www.delcath.com/investors/events/.

About Delcath Systems
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for melphalan hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT Delivery System for Melphalan in Europe. The Delcath Hepatic Delivery System for Melphalan has not been approved for sale in the United States by the U.S. Food and Drug Administration. The Company has initiated plans to investigate Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System for primary liver cancer.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's ability to achieve the estimated average quarterly cash utilization for 2014, the timing of site activation and subject enrollment in the HCC Phase II global clinical  trial, the time to complete the HCC Phase II global clinical trial program and the results of the same, the timing and results of future clinical trials including without limitation Company sponsored clinical trials or investigator initiated trials, continued clinical adoption, use and resulting, sales, if any, of the CHEMOSAT system in Europe including the UK and Germany, the Company's ability to successfully commercialize the Melphalan HDS/ CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the requirements of the FDA's Complete Response Letter and provide the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information:

Investor Contact:

Media Contact:

Michael Polyviou/Doug Sherk

John Carter

EVC Group

EVC Group

212-850-6020

212-850-6021

 


Delcath Systems, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

for the three and six months ended June 30, 2014 and 2013

(Unaudited)

(in thousands, except share and per share data)


















Three months ended June 30,



Six Months Ended June 30,





2014



2013



2014



2013

Product revenue

$

251


$

-


$

561


$

81

Other revenues


-



-



-



300


Total revenue


251



-



561



381

Cost of goods sold


(66)



(332)



(160)



(363)


Gross profit


185



(332)



401



18















Selling, general and administrative1


4,597



6,263



8,416



12,346

Research and development1


1,492



3,992



2,949



8,462


Total operating expenses


6,089



10,255



11,365



20,808



Loss from operations


(5,904)



(10,587)



(10,964)



(20,790)

Change in fair value of warrant liability, net


1,297



5,115



1,092



2,842

Interest income


1



5



2



15

Other expense and interest expense


6



(15)



(8)



(395)



Net loss

$

(4,600)


$

(5,482)


$

(9,878)


$

(18,328)















Loss Per Common Share













Basic loss per common share*

$

(0.49)


$

(0.91)


$

(1.06)


$

(3.22)


Diluted loss per common share*

$

(0.52)


$

(0.91)


$

(1.08)


$

(3.22)















Weighted Average Common Shares













Weighted average number of basic shares outstanding*


9,426,169



6,023,785



9,363,123



5,683,380


Weighted average number of diluted shares outstanding*


9,480,933



6,023,785



9,462,717



5,683,380















Other Comprehensive Income (Loss)













Foreign currency translation adjustments

$

(20)


$

6


$

(22)


$

369



Comprehensive loss

$

(4,620)


$

(5,476)


$

(9,900)


$

(17,959)

















Note 1:














Includes non-cash stock-based compensation as follows:















 Three months ended June 30, 


 Six Months Ended June 30, 




2014


2013


2014


2013



Selling, general and administrative

$

84


$

11


$

240


$

529



Research and development


14



140



77



284



Total stock-based compensation expense

$

98


$

151


$

317


$

813





























* Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

 

DELCATH SYSTEMS, INC.

 Condensed Consolidated Balance Sheets

as of June 30, 2014 and December 31, 2013

(Unaudited)

(in thousands, except share data)
























 June 30, 



December 31,






2014



2013

Assets








Current assets







Cash and cash equivalents 

$

27,284


$

31,249


Accounts receivables, net


172



349


Inventories, net


600



719


Prepaid expenses and other current assets


852



1,711



Total current assets


28,908



34,028


Property, plant and equipment, net


2,421



3,069




Total assets

$

31,329


$

37,097










Liabilities and Stockholders' Equity






Current liabilities







Accounts payable

$

239


$

582


Accrued expenses


4,087



3,740


Warrant Liability


1,075



2,310



Total current liabilities


5,401



6,632


Other non-current liabilities


748



366



Total liabilities


6,149



6,998











Commitments and contingencies 













Stockholders' equity







Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013





Common stock, $.01 par value; 170,000,000 shares authorized; 9,451,870 and 8,394,397 shares issued and 9,447,392 and 8,392,641 shares outstanding at June 30, 2014 and December 31, 2013, respectively *


95



84


Common Stock, to be issued





Additional paid-in capital


264,072



259,102


Accumulated deficit


(239,010)



(229,132)


Treasury stock, at cost; 1,757 shares at June 30, 2014 and December 31, 2013


(51)



(51)


Accumulated other comprehensive income


74



96



Total stockholders' equity


25,180



30,099




Total liabilities and stockholders' equity 

$

31,329


$

37,097










* Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

 

SOURCE Delcath Systems, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Roundee / LinearHub will exhibit at the WebRTC Summit at @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LinearHub provides Roundee Service, a smart platform for enterprise video conferencing with enhanced features such as automatic recording and transcription service. Slack users can integrate Roundee to their team via Slack’s App Directory, and '/roundee' command lets your video conference ...
Digital transformation is too big and important for our future success to not understand the rules that apply to it. The first three rules for winning in this age of hyper-digital transformation are: Advantages in speed, analytics and operational tempos must be captured by implementing an optimized information logistics system (OILS) Real-time operational tempos (IT, people and business processes) must be achieved Businesses that can "analyze data and act and with speed" will dominate those t...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
SYS-CON Events announced today that Secure Channels will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The bedrock of Secure Channels Technology is a uniquely modified and enhanced process based on superencipherment. Superencipherment is the process of encrypting an already encrypted message one or more times, either using the same or a different algorithm.
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...